ERVW-1 and infection: Case-control analysis of the RV144 trial vaccines revealed that the magnitude of immunoglobulin G (IgG) antibodies targeting Env variable regions 1 and 2 (V1V2), correlated with decreased HIV-1 risk, while the titer of specific serum immunoglobulin A (IgA) antibodies correlated with increased risk of infection [26].